As the presence of CSC in PCa [19] and prostate cancer cell lines [20] was recently demonstrated on the basis of the surface antigenic profile CD44+/α2β1hi/CD133+ and CD44+CD24−, respectively, in the present study we aimed to evaluate the contribution of CSC to tumor progression. This evidence concerns the gene CD44 and prostate carcinoma.